The enteric nervous system (ENS) is often called the "second brain" because it contains over 500 million neurons—more than the spinal cord—and operates largely independently of the central nervous system. The ENS controls gut motility, secretion, blood flow, and immune function. In neurodegenerative diseases, the ENS is among the earliest tissues affected, with alpha-synuclein pathology detectable in gut biopsies years before motor symptoms appear.
¶ Cell Types and Organization
- Myenteric (Auerbach's) plexus — located between circular and longitudinal muscle layers; controls motility
- Submucosal (Meissner's) plexus — regulates secretion and blood flow
- Neuronal subtypes: sensory neurons, interneurons, motor neurons
- Neuronal marker (PGP9.5/UCHL1) — pan-neuronal marker
- ChAT (choline acetyltransferase) — cholinergic neurons
- nNOS (neuronal nitric oxide synthase) — inhibitory motor neurons
- CGRP (CALCA) — sensory neurons
- S100β — enteric glia
- Alpha-synuclein pathology — Lewy bodies found in ENS neurons
- Early biomarker — gastrointestinal biopsies detect phosphorylated α-syn
- Prodromal symptoms — constipation, gastroparesis precede motor symptoms
- Braak staging — α-syn spreads from gut to brain via vagus nerve
- GI dysfunction — delayed gastric emptying, small intestinal bacterial overgrowth
- Gut-brain axis — AD pathology affects ENS function
- Amyloid deposition — Aβ found in enteric neurons
- Autonomic dysfunction — vagal degeneration affects gut motility
- Nutritional deficiencies — malabsorption contributes to cognitive decline
- Severe autonomic failure — pronounced GI dysmotility
- α-Synuclein pathology — extensive ENS involvement
- Urinary dysfunction — accompanying bladder dysfunction
- ENS involvement — similar to PD
- Gastrointestinal symptoms — constipation, dysphagia
- Biomarker potential — rectal/colon biopsies for early PD detection
- Gut-based treatments — probiotic, prebiotic interventions
- Levodopa absorption — GI dysfunction affects PD treatment
- Nutritional support — addressing malabsorption
- Gut-focused therapies — prokinetics for gastroparesis
- Microbiome modulation — fecal microbiota transplantation
- Neuroprotective strategies — protecting enteric neurons
- Vagus nerve stimulation — modulating ENS activity
Critically, the ENS represents a key intersection between the gut and the brain in neurodegenerative disease pathogenesis. The bidirectionally connected gut-brain axis provides a pathway through which intestinal pathology may influence central nervous system function, and vice versa.
¶ Cell Types and Markers
The ENS contains multiple distinct neuronal populations:
- Enteric neurons: Cholinergic (excitatory) and nitrergic (inhibitory) neurons controlling motility
- Enteric glial cells: Supporting cells analogous to astrocytes, expressing S100β and GFAP
- Interneurons: Local circuit neurons coordinating peristalsis
- Sensory neurons: Intrinsic primary afferent neurons (IPANs) detecting luminal stimuli
- Secretomotor neurons: Controlling intestinal secretion and blood flow
Key molecular markers:
- HuC/D (pan-neuronal marker)
- ChAT (choline acetyltransferase)
- nNOS (neuronal nitric oxide synthase)
- CGRP (calcitonin gene-related peptide)
- PGP9.5 (ubiquitin C-terminal hydrolase)
The ENS is prominently affected in Parkinson's disease, with gastrointestinal dysfunction occurring in up to 80% of patients, often years before motor symptoms appear[2]. Pathological features include:
- α-Synuclein accumulation: Lewy bodies and Lewy neurites appear in enteric neurons early in PD progression, following the staging scheme proposed by Braak (stages 1-2)[1]
- Neuronal loss: Significant reduction in enteric neuron counts, particularly in the submucosal plexus
- Gut motility dysfunction: Constipation, delayed gastric emptying, and small intestinal bacterial overgrowth
- Barrier disruption: Increased intestinal permeability ("leaky gut")
The ENS may serve as both a site of earliest PD pathology (via vagal nerve propagation to the brain) and a potential biomarker source (via tissue biopsies)[2].
Emerging evidence links gut dysfunction to Alzheimer's disease pathology:
- Gut-brain axis disruption: Altered gut motility and microbiome composition in AD patients
- Intestinal inflammation: Elevated pro-inflammatory cytokines in gut tissue
- Barrier dysfunction: Increased intestinal and blood-brain barrier permeability
- Metabolite effects: Gut-derived metabolites influencing brain function and neuroinflammation[3]
Gastrointestinal dysfunction is increasingly recognized in ALS:
- Malnutrition and weight loss from dysphagia and impaired motility
- Altered gut microbiome composition
- Potential for gut-derived inflammation to influence motor neuron pathology
The ENS serves as the interface between the gut microbiome and the CNS. Microbial metabolites (short-chain fatty acids, bile acids, tryptophan derivatives) directly influence ENS function and can propagate signals to the brain via:
- Vagal afferent pathways
- Systemic circulation
- Immune system modulation[4]
Enteric glial cells support neuronal survival, regulate synaptic transmission, and maintain the intestinal barrier. In neurodegeneration, glial dysfunction may precede and drive neuronal loss.
The ENS communicates with the CNS through sympathetic and parasympathetic (vagus) pathways, providing a anatomical route for pathological protein propagation (e.g., α-synuclein from gut to brain)[1].
- Early biomarkers: Rectal or colonic biopsies can detect early α-synuclein pathology
- Therapeutic targets: Gut-based interventions (probiotics, dietary modifications, microbiome transplantation)
- Drug delivery: Nasal or vagal approaches to bypass blood-brain barrier